X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any payment from Poxel as part of the return of the program.
Lead Product(s): Imeglimin Hydrochloride
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Poxel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Terminated January 14, 2021
Details:
Metavant has conducted a strategic review and has decided not to move forward with the development of Imeglimin. Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 day.
Lead Product(s): Imeglimin Hydrochloride
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sumitomo Pharma Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
